PT2089425E - Compostos anti-angiogénicos - Google Patents

Compostos anti-angiogénicos Download PDF

Info

Publication number
PT2089425E
PT2089425E PT07827123T PT07827123T PT2089425E PT 2089425 E PT2089425 E PT 2089425E PT 07827123 T PT07827123 T PT 07827123T PT 07827123 T PT07827123 T PT 07827123T PT 2089425 E PT2089425 E PT 2089425E
Authority
PT
Portugal
Prior art keywords
compounds
angiogenic compounds
targeting
antibody
linked
Prior art date
Application number
PT07827123T
Other languages
English (en)
Portuguese (pt)
Inventor
Curt Bradshaw
Abhijit Bhat
Jing-Yu Lai
Venkata Doppalapudi
Dingguo Liu
Original Assignee
Covx Technologies Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covx Technologies Ireland Ltd filed Critical Covx Technologies Ireland Ltd
Publication of PT2089425E publication Critical patent/PT2089425E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT07827123T 2006-11-10 2007-11-12 Compostos anti-angiogénicos PT2089425E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86536006P 2006-11-10 2006-11-10
US93983007P 2007-05-23 2007-05-23
US94532907P 2007-06-20 2007-06-20

Publications (1)

Publication Number Publication Date
PT2089425E true PT2089425E (pt) 2011-10-17

Family

ID=39364902

Family Applications (1)

Application Number Title Priority Date Filing Date
PT07827123T PT2089425E (pt) 2006-11-10 2007-11-12 Compostos anti-angiogénicos

Country Status (18)

Country Link
US (3) US8288349B2 (https=)
EP (2) EP2089425B1 (https=)
JP (2) JP4897050B2 (https=)
KR (2) KR101309948B1 (https=)
CN (1) CN101611053B (https=)
AT (1) ATE520712T1 (https=)
AU (1) AU2007318912B2 (https=)
BR (1) BRPI0718591A2 (https=)
CA (1) CA2669207A1 (https=)
DK (1) DK2089425T3 (https=)
IL (1) IL198581A (https=)
MX (1) MX2009005045A (https=)
MY (1) MY146985A (https=)
NO (1) NO20092203L (https=)
NZ (1) NZ576751A (https=)
PL (1) PL2089425T3 (https=)
PT (1) PT2089425E (https=)
WO (1) WO2008056346A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2089425B1 (en) * 2006-11-10 2011-08-17 CovX Technologies Ireland Limited Anti-angiogenic compounds
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
WO2010036930A1 (en) * 2008-09-26 2010-04-01 Javad Parvizi Methods and kits for detecting joint infection
WO2012007896A1 (en) * 2010-07-12 2012-01-19 Covx Technologies Ireland, Ltd. Multifunctional antibody conjugates
JP2014500248A (ja) * 2010-11-05 2014-01-09 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗糖尿病化合物
MX358726B (es) 2011-06-29 2018-09-03 Amgen Inc Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.
BR112014015141A2 (pt) 2011-12-20 2020-10-27 Pfizer Inc. processos aperfeiçoados para preparação de conjugados e ligantes de peptídeo
TW201341401A (zh) 2012-01-09 2013-10-16 Covx Technologies Ireland Ltd 突變抗體及其共軛
EP2831116A1 (en) 2012-03-28 2015-02-04 Amgen Inc. Dr5 receptor agonist combinations
ES2699576T3 (es) 2013-06-12 2019-02-11 Pharis Biotec Gmbh Péptidos con actividades antagonistas contra CXCR4 natural
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
ES2826398T3 (es) 2013-10-15 2021-05-18 Seagen Inc Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco
WO2016209972A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CN108367043A (zh) 2015-12-04 2018-08-03 西雅图基因公司 季铵化的微管溶素化合物的缀合物
KR20180134351A (ko) 2016-03-25 2018-12-18 시애틀 지네틱스, 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
AU2018237683A1 (en) 2017-03-24 2019-10-31 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
EP3617235B1 (en) 2017-04-28 2026-02-18 Ajinomoto Co., Inc. Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5216132A (en) 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
WO1991015515A1 (en) 1990-04-06 1991-10-17 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6080840A (en) 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5733757A (en) * 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6326176B1 (en) * 1997-12-18 2001-12-04 The Scripps Research Institute Aldol condensations by catalytic antibodies
JP2003516121A (ja) 1999-09-27 2003-05-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 不可逆的に結合するエンジニアリング抗体
US6294374B1 (en) * 1999-10-08 2001-09-25 The Scripps Research Institute Use of catalytic antibodies for synthesizing epothilone
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20030045477A1 (en) 2001-07-26 2003-03-06 Fortuna Haviv Peptides having antiangiogenic activity
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
EP1443963B1 (en) * 2001-10-22 2014-05-21 The Scripps Research Institute Antibody targeting compounds
US6737524B2 (en) * 2002-03-25 2004-05-18 Paul K. Smith Activated polyethylene glycol compounds
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
AU2003290330A1 (en) 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2006010057A2 (en) * 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
EA011879B1 (ru) * 2004-09-24 2009-06-30 Эмджин Инк. МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
EP2089425B1 (en) * 2006-11-10 2011-08-17 CovX Technologies Ireland Limited Anti-angiogenic compounds

Also Published As

Publication number Publication date
US20150057431A1 (en) 2015-02-26
CN101611053B (zh) 2015-06-03
NO20092203L (no) 2009-08-10
US20120301431A1 (en) 2012-11-29
IL198581A (en) 2015-10-29
EP2368908A3 (en) 2011-10-12
WO2008056346B1 (en) 2008-12-04
AU2007318912B2 (en) 2011-03-03
AU2007318912A1 (en) 2008-05-15
EP2368908A2 (en) 2011-09-28
EP2089425B1 (en) 2011-08-17
KR101309948B1 (ko) 2013-09-23
MY146985A (en) 2012-10-15
ATE520712T1 (de) 2011-09-15
JP2010509315A (ja) 2010-03-25
EP2089425A2 (en) 2009-08-19
WO2008056346A2 (en) 2008-05-15
JP2012121886A (ja) 2012-06-28
MX2009005045A (es) 2009-11-10
PL2089425T3 (pl) 2012-02-29
BRPI0718591A2 (pt) 2013-12-03
KR20090090331A (ko) 2009-08-25
JP4897050B2 (ja) 2012-03-14
CN101611053A (zh) 2009-12-23
WO2008056346A3 (en) 2008-10-23
US8912148B2 (en) 2014-12-16
US20080166364A1 (en) 2008-07-10
IL198581A0 (en) 2011-08-01
KR20120043028A (ko) 2012-05-03
US8288349B2 (en) 2012-10-16
CA2669207A1 (en) 2008-05-15
NZ576751A (en) 2011-10-28
DK2089425T3 (da) 2011-10-10

Similar Documents

Publication Publication Date Title
IL198581A0 (en) Anti-angiogenic compounds
WO2006094269A3 (en) Anti-angiogenic compounds
MX2009007146A (es) Conjugados porcion del factor ix-polimero que tienen ligadura que se puede liberar.
DOP2012000038A (es) Conjugados de dímeros de pirrolo [1,4] benzodiazepina como agentes anticancerosos
GB2466912A (en) Compositions and methods for treating lysosomal disorders
WO2011006143A3 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases, such as e.g. malaria
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
HN2006000668A (es) Compuestos de quinolina heteroaromaticos
MX2007006179A (es) Tetrahidrocarbazoles como agentes activos para inhibir la produccion del factor de crecimiento endotelial vascular por control de la traduccion.
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
WO2009133573A3 (en) A homeopathic formulation
IL195341A0 (en) Methods and materials for making simvastatin and related compounds
WO2009051670A3 (en) Oxylipin compounds for the treatment of ophthalmic conditions
WO2008070268A3 (en) Pharmaceutical compositions
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
WO2010014258A3 (en) Conjugates having a releasable linkage
WO2009071850A8 (fr) Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
WO2011033064A3 (en) Disulfo-type fluorescent whitening agent compositions
EA201170700A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
SI1900362T1 (sl) Derivati alfa-aminoamida, uporabni pri zdravljenju odvisnosti
WO2007009007A3 (en) Methods of treatment using hydroquinone ansamycins
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
MX2009008249A (es) Composicion farmaceutica que comprende derivado de camptotecina.
WO2010077310A3 (en) Amide derivatives of ethacrynic acid
MX2010008668A (es) Composiciones fungicidas que comprenden 3'-bromo-2,3,4,6'-tetramet oxy-2'-6-dimetilbenzofenona.